Characteristics of the patients report in our study, and other published studies
| Study | Patient | Sex | Age | Years from transplant | TAC* baseline daily dose | TAC* formulation | TAC* baseline concentration (ng/mL) | TAC* 1 (ng/mL) | TAC* 2 (ng/mL) | TAC* 3 (ng/mL) | TAC* reintroduction daily dose | TAC dose adjustment pre-treatment |
| Patients report | 1 | M | 80 (nearest decade) | 9 | 5 mg | Extended release | 5.2 | 4.5 (day 2) | 4.7 (day 4) | 16.2 (day 8) | 5 mg (day 6) | All patients held intake before starting nirmatrelvir/ ritonavir. |
| 2 | M | 40 (nearest decade) | 3 | 6 mg | Immediate release | 6.2 | 2.6 (day 4) | 10.7 (day 6) | 9.0 (day 14) | 4 mg (day 4) | ||
| 3 | F | 59 (nearest decade | 3 | 3 mg | Immediate release | 14.2 | 7.3 (day 2) | 5.8 (day 6) | 1.05 (day 20) | 3 mg (day 6) | ||
| Rose et al12 | 1 | M | 40 | 7 | 11 mg | Immediate release | Not listed | >60 (day 4) | >60 (day 6) | 15 (day 8) | 2 mg (day 9) | Daily dose reduced to 5 mg. |
| 2 | F | 58 | 6 | 5 mg | Immediate release | Not listed | >60 (day 4) | 20 (day 7) | 4 (day 9) | 2 mg (day 8) | Daily dose did not change. | |
| Wang et al13 | 1 | M | 60 (nearest decade) | 9 | 1.5 mg | Immediate release | 6.4 | 4.5 (day 2) | 4.5 (day 4) | 3.4 (day 10) | 1 mg (day 13) | All patients held intake before starting nirmatrelvir/ ritonavir. |
| 2 | M | 70 (nearest decade) | 4 | 1.5 mg | Extended release | 6.6 | 8.6 (day 3) | 6.8 (day 6) | 5.6 (day 9) | 1.5 mg (day 9) | ||
| 3 | F | 50 (nearest decade) | 6 | 5 mg | Extended release | 10.5 | 10.5 (day 2) | 9.1 (day 4) | <2.0 (day 9) | 5 mg (day 9) | ||
| 4 | F | 40 (nearest decade) | 2 | 3 mg | Immediate release | 5.0 | 7.6 (day 2) | 4.4 (day 6) | 2.6 (day 8) | 3 mg (day 9) | ||
| Prikis et al10 | 1 | M | 34 | 9 | 4 mg | Immediate release | Not listed | >30 (day 2) | >30 (day 7) | 8.8 (day 10) | 4 mg (day 10) | Daily dose did not change. |
*TAC corresponds to every tacrolimus blood concentration measurement.